Lota Zoth - Inovio Pharmaceuticals Director
| INO Stock | USD 10.20 0.87 7.86% |
Director
Ms. Lota S. Zoth is Independent Director of the company. Lota Zoth has held senior financial roles in a variety of commercialstage companies, including serving as MedImmune chief financial officer. Prior to joining MedImmune, Ms. Zoth served in financial executive roles with PSINet Inc., Sodexho Marriott Services, Inc., Marriott International and PepsiCo, Inc. Ms. Zoth was also an auditor at Ernst Young, LLP and is a Certified Public Accountant. She has experience of serving on the board of multiple public companies in the biopharmaceutical industry, including Spark Therapeutics currently. since 2019.
| Age | 58 |
| Tenure | 5 years |
| Address | 660 West Germantown Pike, Plymouth Meeting, PA, United States, 19462 |
| Phone | 267 440 4200 |
| Web | https://www.inovio.com |
Lota Zoth Latest Insider Activity
Tracking and analyzing the buying and selling activities of Lota Zoth against Inovio Pharmaceuticals stock is an integral part of due diligence when investing in Inovio Pharmaceuticals. Lota Zoth insider activity provides valuable insight into whether Inovio Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Inovio Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Inovio Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Lota Zoth over six months ago Sale by Lota Zoth of 5700 shares of Inovio Pharmaceuticals |
Inovio Pharmaceuticals Management Efficiency
The company has Return on Asset of (0.3211) % which means that on every $100 spent on assets, it lost $0.3211. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.7955) %, meaning that it generated no profit with money invested by stockholders. Inovio Pharmaceuticals' management efficiency ratios could be used to measure how well Inovio Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 19th of April 2024, Return On Tangible Assets is likely to drop to -0.82. In addition to that, Return On Capital Employed is likely to drop to -1.09. At this time, Inovio Pharmaceuticals' Non Current Assets Total are very stable compared to the past year. As of the 19th of April 2024, Other Current Assets is likely to grow to about 6.9 M, while Total Assets are likely to drop about 131.1 M.Similar Executives
| Found 8 records | DIRECTOR Age | ||
| Tae Kim | Rezolute | 34 | |
| Gilbert Labrucherie | Rezolute | 44 | |
| Hoyoung Huh | Rezolute | 47 | |
| Young Sung | Rezolute | N/A | |
| Yan MBA | Adagene | 49 | |
| David Welch | Rezolute | 56 | |
| Samir Patel | Rezolute | 46 | |
| YoungJin Kim | Rezolute | N/A | |
Management Performance
| Return On Equity | -0.8 | ||||
| Return On Asset | -0.32 |
Inovio Pharmaceuticals Leadership Team
Elected by the shareholders, the Inovio Pharmaceuticals' board of directors comprises two types of representatives: Inovio Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Inovio. The board's role is to monitor Inovio Pharmaceuticals' management team and ensure that shareholders' interests are well served. Inovio Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Inovio Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mark Bagarazzi, Chief Medical Officer | ||
| Mort Collins, Independent Director | ||
| Asli Gevgilili, Chief Officer | ||
| MBA MA, Senior Development | ||
| Adel Mahmoud, Independent Director | ||
| Wendy Yarno, Director | ||
| Ben Matone, Director Relations | ||
| Morton Collins, Independent Director | ||
| Thomas Hong, Manager Relations | ||
| Nancy Wysenski, Director | ||
| Daniel Jordan, VP Operations | ||
| Ann Miller, Director | ||
| Peter Kies, Chief Officer | ||
| Avtar Dhillon, Non-Executive Chairman of the Board | ||
| George Bickerstaff, Director | ||
| Lota Zoth, Director | ||
| Simon Benito, Independent Director | ||
| Jeffrey Skolnik, Senior Development | ||
| Niranjan Sardesai, COO | ||
| Robert Juba, Senior Management | ||
| E MBA, Senior Assurance | ||
| Joseph Kim, CEO and President Director and Member of Fin. Committee | ||
| Jong Kim, President CEO, Director | ||
| Laurent Humeau, Chief Scientific Officer | ||
| Angel Cabrera, Independent Director | ||
| David Weiner, Director | ||
| Robert JD, General Officer | ||
| Jacqueline Shea, President CEO | ||
| PE MBA, Senior Development |
Inovio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Inovio Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.8 | ||||
| Return On Asset | -0.32 | ||||
| Operating Margin | (266.86) % | ||||
| Current Valuation | 123.29 M | ||||
| Shares Outstanding | 23.37 M | ||||
| Shares Owned By Insiders | 1.61 % | ||||
| Shares Owned By Institutions | 18.06 % | ||||
| Number Of Shares Shorted | 2.1 M | ||||
| Price To Earning | (5.43) X | ||||
| Price To Book | 2.20 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inovio Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Complementary Tools for Inovio Stock analysis
When running Inovio Pharmaceuticals' price analysis, check to measure Inovio Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inovio Pharmaceuticals is operating at the current time. Most of Inovio Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Inovio Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inovio Pharmaceuticals' price. Additionally, you may evaluate how the addition of Inovio Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |
Is Inovio Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inovio Pharmaceuticals. If investors know Inovio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inovio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.09) | Revenue Per Share 0.038 | Quarterly Revenue Growth (0.18) | Return On Assets (0.32) | Return On Equity (0.80) |
The market value of Inovio Pharmaceuticals is measured differently than its book value, which is the value of Inovio that is recorded on the company's balance sheet. Investors also form their own opinion of Inovio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Inovio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inovio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Inovio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inovio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Inovio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inovio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.